WO2000077251A2 - Forensic dna profiling method comprising immunological separation step - Google Patents

Forensic dna profiling method comprising immunological separation step

Info

Publication number
WO2000077251A2
WO2000077251A2 PCT/GB2000/002203 GB0002203W WO2000077251A2 WO 2000077251 A2 WO2000077251 A2 WO 2000077251A2 GB 0002203 W GB0002203 W GB 0002203W WO 2000077251 A2 WO2000077251 A2 WO 2000077251A2
Authority
WO
Grant status
Application
Patent type
Prior art keywords
dna
antibody
sperm
epithelial
spermatozoa
Prior art date
Application number
PCT/GB2000/002203
Other languages
French (fr)
Other versions
WO2000077251A3 (en )
Inventor
Matthew James Greenhalgh
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/367Infertility, e.g. sperm disorder, ovulatory dysfunction

Abstract

A DNA profiling method which comprises (i) contacting a sample believed to comprise spermatozoa and/or epithelial cells with antibodies specific for antigens presented on the spermatozoa and/or epithelial cells which antigens are not readily degraded, so as to form antibody-spermatozoa and/or antibody-epithelial cell complexes, (ii) separating the complex(es) from other material in the sample, (iii) isolating DNA from the complex(es) and (iv) determining the specific characteristics of the isolated DNA.

Description

ASSAYS

The present invention relates to improvements in forensic science and in particular to analytical methods for determining the identity of DNA from mixed samples. The forensic biologist is mainly concerned with identifying trace evidence such as blood, semen, saliva and hairs found at the scene of crimes such as murder, rape and assault. DNA profiling has provided a means of identifying the source of such material with a very high degree of certainty. The possibility of a chance match between samples is often presented in court as "less than 1 in a 1000 million", although in reality it can be even rarer. More importantly it is possible to conclusively exclude a suspect as the possible source of a body fluid thus eliminating them from a police inquiry.

Most of the DNA profiling methods in use today use the high degree of variability in tandem repeat regions of the human genome. In these regions, a core sequence is repeated many times, laid end to end. The exact number of repeats varies greatly between people and consequently the length of the minisatellite region containing the repeats are different in different people. By analysing a series of different tandem repeat loci it possible to generate a DNA profile which is highly specific.

Many forensic samples contain a mixture of body fluids from different individuals This is commonly found in sexual assault cases where vaginal swabs taken from the victim will have a mixture of semen and vaginal epithelia present. To simplify the analysis it is very useful to separate the different cell types and obtain a separate DNA profile for the semen.

Currently the only practical method available for isolation of DNA from mixtures of spermatozoa and vaginal epithelial cells is based on differential (preferential) lysis. This method relies on the greater resistance of sperm heads to digestion over other cellular material. The cellular material is extracted from the sample eg. swab into an extraction buffer. The preparation then undergoes relatively mild digestion to lyse cellular material other than sperm. Centrifugation isolates the intact sperm from the other digested cellular components. The sperm then undergo a more aggressive digestion with a long incubation with Proteinase K and dithiothrietol (DTT) to release the DNA. The above method can be inefficient and often does not produce complete separations.

Subsequent typing of genetic markers will reveal three or four alleles rather than the expected one or two that would result from complete separation of the cells within the mixture. The need therefore exists for further improved methods.

We have now devised novel analytical methods which use immuno-capture of male and/or female genetic material from a mixed sample followed by isolation and analysis of the DNA comprised in the male and/or female genetic material. Therefore in a first aspect of the present invention we provide a DNA profiling method which comprises (i) contacting a sample believed to comprise spermatozoa and/or epithelial cells with antibodies specific for antigens presented on the spermatozoa and/or epithelial cells which antigens are not readily degraded, so as to form antibody-spermatozoa and/or antibody- epithelial cell complexes, (ii) separating the complex(es) from other material in the sample, (iii) isolating DNA from the complex(es) and (iv) determining the specific characteristics of the isolated DNA.

The development of the above method allows efficient separation of spermatozoa from epithelial cells prior to DNA characterisation, more easily inteφretable typing patterns and the successful individualisation of the spermatozoa and epithelial DNA. By "not readily degraded" we mean that the antigens can be specifically recognised by the antibodies used in the analytical methods of the invention. That is to say the (target) antigens have not been adversely affected at any time prior to or during their use in the methods of the invention.

By "other material in the sample" we include uncomplexed cellular material and other DNA as may be present in the sample.

By "specific characteristics of the isolated DNA" we include all characteristics of the DNA and nucleotide sequence(s) therein, such as STRs or VNTRs as may be used to determine the identity of the isolated DNA.

The epithelial cells are generally female epithelial cells and usually vaginal epithelial cells.

Any convenient DNA profiling method may be used. These include methods such as short tandem repeat (STR) profiling or profiling using multilocus or single locus probes such as disclosed in European patents nos. 186271 and 238329 respectively. Alternatively the minisatellite variant repeat (MVR) profiling method disclosed in European patent no. 530009 may be used. Convenient and preferred methods include the use of commercially available STR kits such as Profiler Plus™ and PowerPlexlό™ designed to fulfil the requirements of, for example, the US and European courts. Any convenient antibodies may be used provided they are specific for their target antigens. A particular antigen is the FA-2 antigen, this is a sperm specific protein to which monoclonal antibodies (Vic-1) have been raised. (R.K.Naz et al. (1993) Biol. Reprod., 49, 1236-1244). The Vic-1 monoclonal antibody completely blocks human SPA (Sperm Penetration Assay of zona free hamster oocytes), and reduces acrosome reaction and release of acrosin activity. Binding of the antibody does not affect motility of the sperm. Alternatively, the antibody S 19 (target epitope SAGA-1) (A.B. Diekman et al. (1999) FASEB J. 13, 1303- 1313) may be used to bind to all surfaces of the human sperm.

Separation of the antibody-spermatozoa and/or antibody-endothelial cell complexes from other DNA in the sample may be achieved by any convenient technique. These include agglutination and solid phase capture methods. By way of non-limiting example a particular complex may be targeted and captured by antibodies bound directly or indirectly to a solid phase. The solid phase may for example be part of a reaction vessel such as a PCR reaction vessel or it may be a bead or particle such as a magnetic bead. Alternatively sperm heads may be induced to agglutinate through use of, for example an IgG antibody targeted against the antigen and an IgM antibody raised against the invariant portion of the IgG antibody. The complex formed may be harvested by centrifugation or filtration.

The use of magnetic beads to separate complexed material is a preferred aspect of the present invention. The use of such beads allows for example complexed material to be concentrated or drawn closer to an immobilised secondary antibody.

In a particular aspect of the invention we provide a DNA profiling method which comprises (i) contacting a sample believed to comprise both spermatozoa and epithelial cells with antibodies specific for antigens presented on the spermatozoa and epithelial cells respectively which antigens are not readily degraded, so as to form antibody-spermatozoa and antibody-epithelial cell complexes respectively, (ii) separating the complexes from other material in the sample, (iii) isolating DNA from one or both complexes and (iv) determining the specific characteristics of the isolated DNA.

The invention will now be illustrated but not limited by reference to the following specific description. Example and Figures wherein:

Figure 1 shows an intact sperm complete with tail;

Figure 2 shows a discrete head alone; Figure 3 shows the situation where the acrosome at the tip of the sperm head has burst, releasing lytic activity,

Figure 4 shows a pπmary antibody interacting with the antigen, which in turn provides a binding site (biotin) for the Streptavidin coated magnetic particles, Figure 5 shows a pπmary antibody interacting with the antigen, which in turn provides a binding site for the secondary antibody,

Figure 6 shows the pπmary antibody linked directly to a magnetic bead, simplifying the linking of the antigen and the magnetic bead,

Figure 7 shows the gel electrophoresis results of the DNA profiling method of the invention illustrated for convenience at a single genetic locus Lane 1 is a control profiling reaction using blood taken from the male suspect, lane 2 is from spermatozoa from the male suspect, lane 3 is from epithelial matenal from the female victim and lane 4 is a control profiling reaction using blood from the female victim It can be seen there is positive identification of the male and female DNA

Specific description:

We descnbe here a novel technique for the separation of spermatozoa from a mixture of seminal and epithelial matenal The method takes advantage of surface-presented antigens on the sperm head which are absent from other cell types Using (preferably) a high affinity monoclonal or (more likely to cause cross reactivity) a polyclonal serum, a pπmary antibody is applied to the cell mixture The antibodies used as the pπmary will be either (a) biotinylated, or (b) of a species and sub-class, for which there is a commercially available antibody conjugated directly to a magnetic bead, or (c) linked directly to a solid support such as the wall of a tube, or a magnetic bead The pπmary antibody binds to the sperm antigen to form a stable conjugate The conjugate is then retπeved from solution by means of (a) Streptavidin linked magnetic beads, or (b) magnetic beads coated with antibodies with affinity for the invaπant portion of the pπmary antibody, or (c) directly harvested by removal of the supernatant of the tube, or harvest of the magnetic bead through an applied magnetic field

The Primary Antibody

Research based around the search for a male contraceptive pill has identified interference of sperm/oocyte fusion as being a promising mechanism This is being achieved through identification of surface presented proteins which are absent from other cell types. Several such proteins, which have been implicated in sperm/egg fusion, have been identified and reported in the literature (Naz and Vanek. Frontiers in Bioscience 3, e39-48, April 30, 1998). In order for a candidate antigen to be of maximal use, it must be present on the surface of the sperm head regardless of the state of preservation of the sperm head. If the swab is taken quickly after the offence and the sample stored under appropriate conditions, the sperm will be intact, complete with tails (Figure 1). If however the sampling is significantly delayed, the tails may separate, leaving discrete head alone (Figure 2). In extreme cases, it may be that the acrosome at the tip of the sperm head will have burst, releasing lytic activity (Figure 3).

If a immunogenic species unique to the sperm, and is present on all the surfaces above, then it may be used as the target for the primary antibody. Alternatively, an antigen presented on the main body of the sperm head may be adequate.

The antigen is bound by the primary antibody which, in turn, provides a binding site for the Streptavidin coated magnetic particles (Figure 4) or a secondary antibody bound to magnetic particles (Figure 5).

If the primary antibody is linked directly to a solid support such as a magnetic bead, the target antigen and magnetic bead are effectively linked directly (Figure 6).

Antigens

Published research lists a number of proteins which may be of use in immuno- contraception, and which may therefore be useful in the immuno-capture of sperm from a seminal/epithelial mixture. The most important step in the fertilisation process is binding of the sperm with the zona pellucida. Although important for a contraceptive vaccine, an unique surface presented antigen of significant immunogenicity will be a candidate for development as an anchor site for immuno-selection of the sperm head.

Other antigens exist which may not have a direct role in binding of the sperm head to the zona pellucida, but which may be of potential use as sperm specific targets. One such antigen is the carbohydrate moiety of a glycoprotein, called SAGA-1 (Sperm Agglutination Antigen- 1). Magnetic Beads

Dynal UK produces microscopic, uniform, supeφaramagnetic, monodispersed polymer beads (Dynabeads™). The beads are available with a streptavidin coating for conjugation to biotinylated molecules. These beads may be linked to biotinylated antibodies raised against human semen. Alternatively, the beads may be purchased in an activated form which allows the direct coupling of the antibody to the bead. The antibody - bead complex will link to the sperm cells and a magnet is then used to isolate them from the other cell types present in a swab extract.

This system has the advantage over current methods of being more specific in isolating spermatozoa prior to DNA extraction. It also produces far cleaner DNA which is less likely to contain PCR inhibitors. Additionally the method requires fewer tube to tube transfers minimising sample loss, contamination and the possibility of operator error. These are all important considerations with forensic samples.

Procedure

We have purchased antibodies against pooled human semen which have been prepared in sheep. The manufacturers (Biogenesis) have purified this product and biotinylated it. This material is incubated with the streptavidin coated Dynal beads to produce the antibody - bead complex. An aliquot of the complex is added to mixed cell suspension which has been extracted from the vaginal swab. This is incubated for a short while to allow the bead - antibody complex to link on to spermatozoa in the suspension. The new bead-antibody-sperm complex is then pulled to the side of the tube using a magnetic concentrator (Dynal). The pellet is re-suspended in fresh buffer and washed several times to remove all traces of epithelial cells. The purified sperm component then undergoes digestion with proteinase K and DTT to liberate the DNA.

Example:

Characterisation of male and female DNA from a mixed forensic sample

A post coital swab is taken from an alleged victim and treated as follows. Cellular material is extracted by vortexing the swab in phosphate buffered saline and the cells harvested by centrifugation. These are re-suspended in a small volume (300μl) of phosphate buffered saline and incubated with an excess of an anti-sperm antibody. The antibody-sperm complex formed is then targeted by an excess of the secondary antibody/ magnetic bead complex. (This may also be achieved by having a biotinylated primary antibody being bound by an excess of streptavidin coated magnetic beads). The complex is harvested magnetically and undergoes a series of washes to remove the unbound cellular material. The complex is heated to 80°C to denature the antibodies and release the sperm heads.

The DNA can then be extracted by a range of established methods. (Phenol/chloroform, Chelex 100 etc.).

STR profiling is then effected using a PE Profiler Plus™ (Profiler Plus Handbook) kit according to manufacturers instructions. The primers, buffer and thermostable DNA polymerase (such as AmpliTaq Gold™) are added to the PCR tubes (as above). Conveniently 28 cycles of PCR amplification are effected using a 9700 thermal cycler (Perkin Elmer).

The resulting material is separated using gel electrophoresis and the results are shown in Figure 7 (for convenience these illustrate the results at one locus only). Lane 1 is a control profiling reaction using blood taken from the male suspect, lane 2 is from spermatazoa from the male suspect, lane 3 is from epithelial material from the female victim and lane 4 is a control profiling reaction using blood from the female victim. It can be seen there is positive identification of the male and female DNA.

Claims

Clai s:
1. A DNA profiling method which comprises (i) contacting a sample believed to comprise spermatozoa and/or epithelial cells with antibodies specific for antigens presented on the spermatozoa and/or epithelial cells which antigens are not readily degraded, so as to form antibody-spermatozoa and/or antibody-epithelial cell complexes, (ii) separating the complex(es) from other material in the sample, (iii) isolating DNA from the complex(es) and (iv) determining the specific characteristics of the isolated DNA.
2. A method as claimed in claim 1 wherein the antibodies are biotinylated for separation in step (ii).
3. A method as claimed in claim 1 wherein the antibodies are conjugated to magnetic beads for separation in step (ii).
4. A method as claimed in claim 1 wherein secondary antibodies are used for separation in step (ii).
5. A DNA profiling method which comprises (i) contacting a sample believed to comprise both spermatozoa and epithelial cells with antibodies specific for antigens presented on the spermatozoa and epithelial cells respectively which antigens are not readily degraded, so as to form antibody-spermatozoa and antibody-epithelial cell complexes respectively, (ii) separating the complexes from other material in the sample, (iii) isolating DNA from one or both complexes and (iv) determining the specific characteristics of the isolated DNA.
6. A method as claimed in any one of the previous claims wherein the antibodies for at least one antigen are monoclonal.
7. A method as claimed in any one of the previous claims wherein the antibodies have been raised to the FA2 antigen.
8. A method as claimed in any one of claims 1-6 wherein the antibodies have been raised to the Sperm Agglutination Antigen- 1 (SAGA-1).
PCT/GB2000/002203 1999-06-11 2000-06-07 Forensic dna profiling method comprising immunological separation step WO2000077251A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB9913556.8 1999-06-11
GB9913556A GB9913556D0 (en) 1999-06-11 1999-06-11 Assays

Publications (2)

Publication Number Publication Date
WO2000077251A2 true true WO2000077251A2 (en) 2000-12-21
WO2000077251A3 true WO2000077251A3 (en) 2001-05-25

Family

ID=10855131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002203 WO2000077251A3 (en) 1999-06-11 2000-06-07 Forensic dna profiling method comprising immunological separation step

Country Status (2)

Country Link
GB (1) GB9913556D0 (en)
WO (1) WO2000077251A3 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320891B2 (en) 2004-09-10 2008-01-22 Promega Corporation Methods and kits for isolating sperm cells
EP2144993A1 (en) * 2007-05-09 2010-01-20 Applied Biosystems, LLC Methods and systems for differential extraction
WO2015189208A1 (en) * 2014-06-11 2015-12-17 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Methods for separating cells

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0186271A1 (en) * 1984-11-12 1986-07-02 THE LISTER INSTITUTE OF PREVENTIVE MEDICINE Royal National Orthopaedic Hospital Method of characterising a test sample of genomic DNA
EP0238329A2 (en) * 1986-03-19 1987-09-23 Zeneca Limited Improvements in genetic probes
US4741998A (en) * 1985-06-05 1988-05-03 The University Of Virginia Alumni Patents Foundation Monoclonal antibody to MHS-5: a new probe for sexual assault analyses
US5047508A (en) * 1985-06-05 1991-09-10 The University Of Virginia Alumni Patents Foundation Monoclonal antibody to MHS-5; a new probe for sexual assault analysis
EP0530009A2 (en) * 1991-08-27 1993-03-03 Zeneca Limited Method of characterising genomic DNA
US5436157A (en) * 1989-03-03 1995-07-25 The University Of Virginia Alumni Patents Foundation Human intra-acrosomal sperm antigen
US5605803A (en) * 1989-03-03 1997-02-25 University Of Virginia Alumni Patents Foundation Human sperm diagnostic
WO1998028622A1 (en) * 1996-12-20 1998-07-02 Fodstad Oeystein Method for characterization of abnormal cells
US5830472A (en) * 1996-06-28 1998-11-03 The University Of Virginia Patent Foundation Purified sperm surface antigen, monoclonal antibody therefor and applications therefor
WO1999042129A1 (en) * 1998-02-23 1999-08-26 University Of Virginia Patent Foundation Purified sperm surface antigen, monoclonal antibody therefor and application therefor

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0186271A1 (en) * 1984-11-12 1986-07-02 THE LISTER INSTITUTE OF PREVENTIVE MEDICINE Royal National Orthopaedic Hospital Method of characterising a test sample of genomic DNA
US4741998A (en) * 1985-06-05 1988-05-03 The University Of Virginia Alumni Patents Foundation Monoclonal antibody to MHS-5: a new probe for sexual assault analyses
US5047508A (en) * 1985-06-05 1991-09-10 The University Of Virginia Alumni Patents Foundation Monoclonal antibody to MHS-5; a new probe for sexual assault analysis
EP0238329A2 (en) * 1986-03-19 1987-09-23 Zeneca Limited Improvements in genetic probes
US5436157A (en) * 1989-03-03 1995-07-25 The University Of Virginia Alumni Patents Foundation Human intra-acrosomal sperm antigen
US5605803A (en) * 1989-03-03 1997-02-25 University Of Virginia Alumni Patents Foundation Human sperm diagnostic
EP0530009A2 (en) * 1991-08-27 1993-03-03 Zeneca Limited Method of characterising genomic DNA
US5830472A (en) * 1996-06-28 1998-11-03 The University Of Virginia Patent Foundation Purified sperm surface antigen, monoclonal antibody therefor and applications therefor
WO1998028622A1 (en) * 1996-12-20 1998-07-02 Fodstad Oeystein Method for characterization of abnormal cells
WO1999042129A1 (en) * 1998-02-23 1999-08-26 University Of Virginia Patent Foundation Purified sperm surface antigen, monoclonal antibody therefor and application therefor

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320891B2 (en) 2004-09-10 2008-01-22 Promega Corporation Methods and kits for isolating sperm cells
US8993292B2 (en) 2007-01-16 2015-03-31 Applied Biosystems Llc Methods and systems for differential extraction
EP2144993A1 (en) * 2007-05-09 2010-01-20 Applied Biosystems, LLC Methods and systems for differential extraction
WO2015189208A1 (en) * 2014-06-11 2015-12-17 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Methods for separating cells

Also Published As

Publication number Publication date Type
WO2000077251A3 (en) 2001-05-25 application
GB9913556D0 (en) 1999-08-11 grant

Similar Documents

Publication Publication Date Title
US6255477B1 (en) Particles having a magnetic core and outer glass layer for separating biological material
US6153373A (en) Method for sex determination of mammalian offspring
US5484701A (en) Method for sequencing DNA using biotin-strepavidin conjugates to facilitate the purification of primer extension products
US5665539A (en) Immuno-polymerase chain reaction system for antigen detection
US5200313A (en) Nucleic acid hybridization assay employing detectable anti-hybrid antibodies
US4427782A (en) Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis
US4908318A (en) Nucleic acid extraction methods
Lydersen et al. Human-specific nuclear protein that associates with the polar region of the mitotic apparatus: distribution in a human/hamster hybrid cell
US5523231A (en) Method to isolate macromolecules using magnetically attractable beads which do not specifically bind the macromolecules
Haukanes et al. Application of magnetic beads in bioassays
US5461145A (en) Sexing method of bovine embyros
Strand et al. Type-C RNA virus gene expression in human tissue
EP0288737A1 (en) Rapid hybridization assay using latex-immobilized probe
Goldsmith et al. Adsorption protein of the bacteriophage fd: isolation, molecular properties, and location in the virus
Rosa et al. A mammalian tRNA His-Containing antigen is recognized by the polymyosits-specific antibody antijo-1
Jacob et al. Binding of a monoclonal anti-DNA autoantibody to identical protein (s) present at the surface of several human cell types involved in lupus pathogenesis.
US6368800B1 (en) Kits for isolating biological target materials using silica magnetic particles
US5973138A (en) Method for purification and manipulation of nucleic acids using paramagnetic particles
US6649419B1 (en) Method and apparatus for protein manipulation
Koch et al. An association between actin and the major histocompatibility antigen H–2
Booth et al. Detection of bovine viral diarrhoea virus antigen and RNA in oviduct and granulosa cells of persistently infected cattle
US7173124B2 (en) Isolation of nucleic acid
US6090935A (en) Isolation of nucleic acid
US6194562B1 (en) Endotoxin reduction in nucleic acid purification
Handyside Time of commitment of inside cells isolated from preimplantation mouse embryos

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP